Combined NK-CIK and PD-1 inhibitor (nivolumab), an effective immunotherapy for treating intrahepatic lymphoepithelioma-like cholangiocarcinoma unassociated with EBV infection: Two case reports and a…

Overview of attention for article published in Frontiers in oncology, January 2023

Altmetric Badge

About this Attention Score

Good Attention Score compared to outputs of the same age (72nd percentile)
High Attention Score compared to outputs of the same age and source (93rd percentile)

Mentioned by

twitter: 8 X users

Citations

dimensions_citation: 4 Dimensions

Readers on

mendeley: 4 Mendeley

Summary X Dimensions citations

So far, Altmetric has seen 8 X posts from 8 X users, with an upper bound of 26,619 followers.

Combined NK-CIK and PD-1 inhibitor (nivolumab), an effective immunotherapy for treating intrahepatic lymphoepithelioma-like cholangiocarcinoma unassociated with EBV infection: Two case reports and a literature review by Alen Sam Saji https://t.co/iSNO98HzW

03 Mar 2023

Reply Repost Favourite

03 Mar 2023

Reply Repost Favourite

RT @FrontOncology: New research: Combined NK-CIK and PD-1 inhibitor (nivolumab), an effective immunotherapy for treating intrahepatic lymph…

01 Feb 2023

Reply Repost Favourite

RT @FrontOncology: New research: Combined NK-CIK and PD-1 inhibitor (nivolumab), an effective immunotherapy for treating intrahepatic lymph…

31 Jan 2023

Reply Repost Favourite

This page shows the most recent X posts that mention this research output.

Click here to find out how to access more activity, including 4 additional X posts.